192 filings
Page 7 of 10
424B5
igd36zdd1affmz
24 Jan 17
Prospectus supplement for primary offering
12:00am
424B5
44lk0
19 Jan 17
Prospectus supplement for primary offering
12:00am
6-K
8wyiu
11 Jan 17
Affimed Provides Update on NK-Cell Immuno-Oncology Platform
12:00am
6-K
ibj7m2nh79ftk
5 Jan 17
Transforming Immuno - Oncology Using Next - Generation Immune Cell Engagers Corporate Presentation January 2017
12:00am
6-K
mc09rba pwc2ers
4 Jan 17
Agreement Brings Together MD Anderson’s Natural Killer Cell and Affimed’s Antibody-based Technologies
12:00am
424B5
1ooxoo28dnpjx
15 Dec 16
Prospectus supplement for primary offering
12:00am
6-K
200ggue96hmenx4gqe0
6 Dec 16
Current report (foreign)
12:00am
6-K
8syqhalugrxyg9ra
2 Nov 16
Index to Condensed Consolidated Financial Statements
12:00am
6-K
1pmj2vyms9u5gmrd2q
10 Aug 16
Index to Condensed Consolidated Financial Statements
12:00am
6-K
lqoblcnk
1 Jul 16
Current report (foreign)
12:00am
6-K
xpil9w0pc64231alhn2
22 Jun 16
Current report (foreign)
12:00am
6-K
vgcre92gid
23 May 16
Affimed Announces Annual General Meeting of Shareholders
12:00am
6-K
gvhhd ophddk7ipc2
18 May 16
Index to Condensed Consolidated Financial Statements
12:00am
6-K
w8pddio6va2
30 Mar 16
Affimed Reports Financial Results for Fourth Quarter
12:00am
6-K
wk57novav yd92
25 Jan 16
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA®(pembrolizumab) for Patients with Hodgkin Lymphoma
12:00am
6-K
27fjuc
21 Jan 16
Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board
12:00am
6-K
gpydoh
8 Jan 16
Transforming Immuno - Oncology Using Next - Generation Immune Cell Engagers Corporate Presentation January 2016
12:00am
6-K
0c0vg8dbn1gdfzpjd
16 Dec 15
Extraordinary General Meeting of Shareholders
12:00am
6-K
c3ao m3xl4
7 Dec 15
Affimed Presents Data Comparing T-cell- and NK-cell-engaging TandAbs AFM11 and AFM12 at ASH
12:00am